LM

Constellation Insurance Selects SS&C to Scale Commercial Mortgage Operation

Retrieved on: 
Thursday, March 9, 2023
Constellation, LM, Insurance, Accounting, Real estate investment trust, SS, Real estate, SS&C, Automation, Surveying

WINDSOR, Conn., March 9, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced Constellation Insurance, Inc. has selected SS&C Precision LM™ to help manage its growing commercial mortgage portfolio. Precision LM loan origination and servicing software will support pipeline tracking, loan servicing, accounting, asset management and regulatory reporting for its growing commercial mortgage portfolio—all on a single integrated platform.

Key Points: 
  • Insurance holding company with a $1.6 billion loan portfolio chooses next-generation SS&C Precision LM platform to improve efficiency, profitability and risk control
    WINDSOR, Conn., March 9, 2023 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced Constellation Insurance, Inc. has selected SS&C Precision LM™ to help manage its growing commercial mortgage portfolio.
  • Precision LM loan origination and servicing software will support pipeline tracking, loan servicing, accounting, asset management and regulatory reporting for its growing commercial mortgage portfolio—all on a single integrated platform.
  • "We were impressed by SS&C's expertise, infrastructure, and continued enhancement to its commercial mortgage technology," said Timothy Biggs, Vice President, Mortgages and Real Estate at Constellation.
  • "Precision LM is a robust and scalable solution, which will provide increased data and automation and improve efficiency and accuracy.

1935 Voisin C25 Aerodyne and 1964 Ferrari 250 LM Named Best in Show at The Amelia's Record-Setting Motoring Weekend

Retrieved on: 
Wednesday, March 8, 2023
Carbon, Place Bellecour, British Racing Drivers' Club, Sale, Racing, North American Racing Team, Indianapolis Motor Speedway Museum, Community, NASCAR, Aerodyne, Cop, Porsche, Aerodyne Technologies, Drink, Eye, Personal Car Communicator, Amelia Island Concours d'Elegance, Volunteering, Future, Acura, Ride, NART, Le Mans, Tree, LM, Ford, Integra, McLaren, Golf club, AMG, Attention, Foire de Lyon, Beer, Concours, Broad arrow, Community Hospice & Palliative Care, McKeel Hagerty, Club, The Ritz-Carlton Hotel Company, C25, Palliative care, Arrow, Corvette, Organization, Education, NASCAR Cup Series, P1, Auction, Nightclub, Quest, Ferrari, Daytona

AMELIA ISLAND, Fla., March 8, 2023 /PRNewswire/ -- A 1935 Voisin C25 Aerodyne and a 1964 Ferrari 250 LM were crowned Best in Show at The Amelia Concours d'Elegance - its 28th annual event.

Key Points: 
  • AMELIA ISLAND, Fla., March 8, 2023 /PRNewswire/ -- A 1935 Voisin C25 Aerodyne and a 1964 Ferrari 250 LM were crowned Best in Show at The Amelia Concours d'Elegance - its 28th annual event.
  • The Aerodyne was Voisin's "Car of the Future," an automobile that sought to capitalize upon the public's growing fascination with streamlining and aerodynamics.
  • In the spring of 1935, Voisin displayed this special Aerodyne at the Lyon Fair and at the concours d'elegance at the Place Bellecour.
  • The Best in Show Concours de Sport was awarded to a 1964 Ferrari 250 LM displayed by Indianapolis Motor Speedway Museum of Indianapolis, Indiana.

Elbit Systems to Showcase Platforms at DSEI Japan 2023

Retrieved on: 
Wednesday, March 8, 2023
Tracking system, IR, Head-up display, G.I. Joe: A Real American Hero, IDF, Iron Fist, ROOK, LM, Acquisition, UAV, MALE, RCWS, Remote controlled weapon station, Electronic countermeasure, Elbit Systems, UAS, Multifunction Advanced Data Link, LAD, Atmosphere, APS, HUD, ECM, Elbit Hermes 900, SAR, Pod, Japan, Gull, Safety, Hermes, Satellite navigation device

HAIFA, Israel, March 8, 2023 /PRNewswire/ -- Elbit Systems will participate at DSEI Japan between15-17 March 2023 in Tokyo and exhibit a wide range of products and systems at its booth with both visual and interactive displays.

Key Points: 
  • HAIFA, Israel, March 8, 2023 /PRNewswire/ -- Elbit Systems will participate at DSEI Japan between15-17 March 2023 in Tokyo and exhibit a wide range of products and systems at its booth with both visual and interactive displays.
  • Elbit Systems is known for its groundbreaking solutions that have led to dramatic changes on the battlefield.
  • At its stand in Hall 8 booth H8-210, Elbit Systems will present a range of cutting edge technological solutions that help address both current and emerging operational needs of armed forces.
  • The Iron Fist Active Protection System (APS) provides armored platforms with 360-degree protection from a wide variety of anti-armor threats.

The Moon Labs Announces the Opening of 'NFT Korea Festival 2023', a Global NFT Festival at DDP

Retrieved on: 
Saturday, March 4, 2023
ASIA, Non-fungible token, Blue, LM, Exhibition, Sutu, DDP, Ecosystem, Dongdaemun Design Plaza, Kumho Art Hall, NFT, Moon, Cryptocurrency, Film industry, OpenSea

A leading global NFT art gallery, Superchief Gallery NFT, is curating the NFTs of this festival with over 100 star NFT artists such as Dave Krugman, Sutu, Light feet, and Korean local NFT artists such as Sandbang and Cloudy Night.

Key Points: 
  • A leading global NFT art gallery, Superchief Gallery NFT, is curating the NFTs of this festival with over 100 star NFT artists such as Dave Krugman, Sutu, Light feet, and Korean local NFT artists such as Sandbang and Cloudy Night.
  • Superchief Gallery NFT, a co-host of this NFT Korea Festival 2023, is the world's first physical NFT gallery in USA, established in March 2021.
  • An official from The Moon Labs said, "The NFT Korea Festival will become the representative NFT festival in Korea which will go beyond being a simple NFT exhibition and become a large gathering of the global NFT ecosystem to share the visions and insights of its leaders together.
  • The NFT Korea Festival is the largest gathering of Web3 and NFT industry leaders, artists, and enthusiasts in Korea.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 2, 2023
Maker, NYSE, IBM, Survival, MRI, Biologics license application, ESS, Register, P.C, CFR, Letter, Prospectus, CSF, ORR, Safety, Overalls, Element, IPO, CNS, Risk, Form 10-Q, Marketing, Therapy, Radiation, BLA, Bank statement, Neuroblastoma, Advisory Committee, ESI, OS, Brain, Memorial Sloan Kettering Cancer Center, Registration statement, Shareholder, Class, Knowledge, News, Sale, RTF, Rule, LM, Person, FDA, Observation, Central nervous system, Disclosure, Form 10-K, Patient, Database, Spinal cord, Placebo, Partnership, NB, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Plaintiff, Form, Defendant

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 25, 2023
Maker, Overalls, Memorial Sloan Kettering Cancer Center, Prospectus, Observation, Registration statement, Neuroblastoma, IPO, Safety, Therapy, Central nervous system, Advisory Committee, ESS, LM, RTF, Patient, Database, MRI, NB, Biologics license application, IBM, Class, Sale, Knowledge, Spinal cord, Register, NYSE, Partnership, CSF, Brain, OS, CNS, Letter, ORR, Bank statement, Placebo, Form 10-K, Rule, ESI, Person, Marketing, News, Shareholder, Survival, CFR, BLA, Risk, FDA, Element, P.C, Radiation, Form 10-Q, Disclosure, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, February 23, 2023
BAM, Safety, Society, Therapy, University, Hand, SNO, Investigational New Drug, Drug development, GMP, IND, LM, Webcast, FDA, Patient, PSTV, CNS, Education, Moses Austin, CMC, Plus Therapeutics, Food and Drug Administration, Rhenium, Bangladesh Technical Education Board, GBM, Food, Ependymoma, Pharmaceutical industry, Vaccine, Cryptocurrency, Medical device

AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided an overview of recent business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided an overview of recent business highlights.
  • Awarded $17.6 million CPRIT grant to support Phase 1 and Phase 2 clinical development of rhenium (186Re) obisbemeda for LM.
  • During the fourth quarter of 2022, the Company received its first CPRIT grant funds of approximately $1.9 million.
  • Execute corporate partnerships to expand the business opportunities for Plus Therapeutics’ unique CNS oncology platform.

A2LA Director of Government Relations, Randall Querry, Selected for Leadership Maryland Class of 2023

Retrieved on: 
Thursday, February 23, 2023
Knowledge, Food, Organization, Laboratory, LM, Economic development, International Laboratory Accreditation Cooperation, Accreditation, Environment, Calibration, Education, Directory, Health, Management, Nursing, Information technology

FREDERICK, Md., Feb. 23, 2023 /PRNewswire-PRWeb/ -- The American Association for Laboratory Accreditation (A2LA), one of the largest conformity assessment accreditation bodies in the world, is proud to announce that Randall Querry, Director of Government Relations, has been selected as one of 53 people to participate in the exceptional program, Leadership Maryland.

Key Points: 
  • I'm looking forward to bringing what I'll learn through Leadership Maryland to our team at A2LA."
  • Leadership Maryland is a statewide professional development program for senior-level executives who have made significant contributions to their industries and communities.
  • "We are excited to announce our next class and welcome these accomplished and motivated individuals to Leadership Maryland," said David Fike '16 (LM) president and CEO, Leadership Maryland, in a recent press release.
  • For more information about Leadership Maryland, please visit leadershipmd.org , call 410-841-2101, or email [email protected] .

Davey Perkins' NFT Auction Ended in Just One Minute on playNomm NFT Marketplace For a High Buy Out Price

Retrieved on: 
Tuesday, February 14, 2023
LM, Ecosystem, Shadow, NFT, DDP, Cryptocurrency

SEOUL, KOREA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- On February 13th, on NFT marketplace playNomm (CEO, Sung-Uk Moon), Davey Perkins’, one of Superchief Gallery NFT artists, NFT has been sold out as soon as the auction started.

Key Points: 
  • SEOUL, KOREA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- On February 13th, on NFT marketplace playNomm (CEO, Sung-Uk Moon), Davey Perkins’, one of Superchief Gallery NFT artists, NFT has been sold out as soon as the auction started.
  • Davey Perkins is a freelance illustrator in Germany, who focuses on character design with a sci-fi concept.
  • As a pre-event of the NFT Korea Festival, three NFT auction events were held on playNomm NFT marketplace.
  • The NFT Korea Festival is an event being held on March 7th and 8th 2023, at DDP, Seoul, South Korea.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 14, 2023
Maker, Bank statement, Prospectus, Rule, CFR, Safety, NYSE, LM, Placebo, CSF, Person, Partnership, Memorial Sloan Kettering Cancer Center, NB, Brain, Element, Form 10-Q, Radiation, News, Form 10-K, CNS, Risk, IPO, ORR, Knowledge, Survival, RTF, Marketing, Neuroblastoma, FDA, Observation, ESI, Spinal cord, IBM, Advisory Committee, OS, MRI, Patient, Disclosure, Database, Sale, Letter, Therapy, Central nervous system, BLA, Registration statement, Register, Biologics license application, P.C, ESS, Class, Overalls, Shareholder, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.